Trials
4 active
16 in total · 10 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Participants previously randomised in the TITANIA or PROSPERO predecessor studies will receive Tozorakimab in ROMEO according to this dose regimen”In the company’s words, NCT07566195 on ClinicalTrials.gov
- Tested for
- Viral Lung Infection and Acute Respiratory Failure, Chronic Obstructive Pulmonary Disease, COPD, Asthma
- Main trialPhase 3
- “The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.”In the company’s words, NCT05624450 on ClinicalTrials.gov
- Other names
- MEDI3506
Other drugs for Viral Lung Infection and Acute Respiratory Failure
- APC-0101Aerogen Pharma Limited · Phase 3
- ExoFloDirect Biologics, LLC · Phase 3
- Aerosolized CalfactantONY · Phase 3
- LEAF-4L6715LEAF4Life, Inc. · Phase 3
- STSA-1002Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 3
- SecretomePT. Prodia Stem Cell Indonesia · Phase 1/2
Coming up3
- 7 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
- 4 Nov 2027Phase 3 trial completes · ClinicalTrials.gov
- 29 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials16
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 4 Nov 2027 | Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | |
| Phase 3Recruiting | 29 Dec 2028 | Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations | |
| Phase 2Recruiting | 7 Jun 2027 | Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids | |
| Phase 3Completed | 19 Jan 2026 | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations | |
| Phase 3Completed | 19 Jan 2026 | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. | |
| Phase 3Completed | 26 Feb 2026 | Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO). | |
| Phase 3Completed | 6 Mar 2026 | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations | |
| Phase 2Completed | 21 Jul 2022 | Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis | |
| Phase 2Completed | 12 Dec 2022 | Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma | |
| Phase 2Completed | 16 May 2023 | A Phase 2b Diabetic Kidney Disease Study | |
| Phase 2Completed | 30 May 2023 | A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis | |
| Phase 2Completed | 21 Apr 2026 | A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils | |
| Phase 1Completed | 7 Feb 2022 | Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants | |
| Phase 1Completed | 9 Sep 2024 | A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers | |
| Phase 1Completed | 25 Nov 2025 | An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab | |
| Phase 2Authorised | not given | Effects of Anti-IL33 (Tozorakimab) Upon Airway Inflammation, Remodelling and Response to Exacerbation Triggers in COPD (The MAB Trial) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026